Acadia Pharmaceuticals 2025 Q3 Earnings Net Income Surges 119% as Revenue Grows 11%

Acadia Pharmaceuticals (ACAD) reported robust Q3 2025 results, surpassing expectations with 11.3% revenue growth and a 119.1% increase in net income. , reflecting strong performance in core products NUPLAZID and DAYBUE.

Revenue

, . , . The expansion of the field force and named patient programs outside the U.S. further bolstered DAYBUE’s performance.

Earnings/Net Income

, with net income jumping to $71.78 million—a new 20-year high. This marks a significant acceleration in profitability, driven by strong revenue growth and a tax benefit from the One Big Beautiful Bill Act. The earnings performance underscores Acadia’s ability to deliver value to shareholders.

Post-Earnings Price Action Review

, .

CEO Commentary

Catherine Owen Adams highlighted the “strong quarter,” emphasizing record sales and strategic priorities such as achieving $1 billion in 2025 revenue, advancing pipeline candidates like ACP-204 and trofinetide, and expanding global reach. The CEO expressed confidence in the company’s ability to drive innovation and growth.

Guidance

, . , . The updated guidance includes international named patient programs, reflecting broader commercialization efforts.

Additional News

In recent weeks, Acadia announced key leadership changes: Catherine Owen Adams was appointed Chairperson of the BIO Emerging Companies section, and Konstantina Katcheves joined as Senior Vice President, Chief Business and Strategy Officer. These moves aim to strengthen business development and pipeline expansion. Additionally, the company initiated a Phase 2 trial for ACP-204 in Lewy Body Dementia Psychosis and a Phase 3 trial for trofinetide in Japan, underscoring its commitment to advancing therapeutic innovation.